ADMS - Adamas Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5184.12M
Enterprise Value 3138.05M
Trailing P/E N/A
Forward P/E 1-2.64
PEG Ratio (5 yr expected) 1-0.04
Price/Sales (ttm)3.81
Price/Book (mrq)4.30
Enterprise Value/Revenue 32.86
Enterprise Value/EBITDA 6-1.37

Trading Information

Stock Price History

Beta (3Y Monthly) 2.46
52-Week Change 3-66.26%
S&P500 52-Week Change 33.49%
52 Week High 320.63
52 Week Low 34.20
50-Day Moving Average 36.10
200-Day Moving Average 36.19

Share Statistics

Avg Vol (3 month) 3377.75k
Avg Vol (10 day) 3652.87k
Shares Outstanding 527.77M
Float 18.45M
% Held by Insiders 12.11%
% Held by Institutions 1114.84%
Shares Short (Aug 15, 2019) 43.76M
Short Ratio (Aug 15, 2019) 410.69
Short % of Float (Aug 15, 2019) 421.26%
Short % of Shares Outstanding (Aug 15, 2019) 413.52%
Shares Short (prior month Jul 15, 2019) 44.58M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin -241.41%
Operating Margin (ttm)-212.17%

Management Effectiveness

Return on Assets (ttm)-26.88%
Return on Equity (ttm)-125.84%

Income Statement

Revenue (ttm)48.28M
Revenue Per Share (ttm)1.76
Quarterly Revenue Growth (yoy)67.80%
Gross Profit (ttm)33.41M
EBITDA -101.03M
Net Income Avi to Common (ttm)-116.56M
Diluted EPS (ttm)-4.25
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)168.65M
Total Cash Per Share (mrq)6.07
Total Debt (mrq)133.12M
Total Debt/Equity (mrq)311.74
Current Ratio (mrq)7.27
Book Value Per Share (mrq)1.54

Cash Flow Statement

Operating Cash Flow (ttm)-90.65M
Levered Free Cash Flow (ttm)-64.55M